Royal Bank of Canada Purchases 24,375 Shares of PROCEPT BioRobotics Corporation $PRCT

Royal Bank of Canada lifted its holdings in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 167.1% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 38,962 shares of the company’s stock after buying an additional 24,375 shares during the period. Royal Bank of Canada owned approximately 0.07% of PROCEPT BioRobotics worth $975,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd increased its position in shares of PROCEPT BioRobotics by 436.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after acquiring an additional 746 shares during the last quarter. Center for Financial Planning Inc. purchased a new position in PROCEPT BioRobotics in the fourth quarter worth $40,000. Cache Advisors LLC bought a new position in PROCEPT BioRobotics in the 1st quarter valued at $42,000. US Bancorp DE grew its stake in PROCEPT BioRobotics by 175.7% in the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company’s stock valued at $60,000 after purchasing an additional 1,079 shares during the period. Finally, Kestra Advisory Services LLC purchased a new stake in shares of PROCEPT BioRobotics during the 4th quarter valued at $68,000. 89.46% of the stock is owned by institutional investors.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms reminded investors that September 22, 2026 is the deadline to seek appointment as lead plaintiff in a class action covering purchases of PROCEPT stock from February 28, 2024, through February 25, 2026. These announcements are largely duplicative investor-solicitation notices rather than new company disclosures. Kaplan Fox class-action deadline notice
• Negative Sentiment: The lawsuits allege that PROCEPT failed to disclose inventory problems, including excess customer inventory tied to late-quarter bulk discounts, while investors focused on handpiece sales as a measure of procedure demand. The allegations claim that later revelations led to a substantial stock decline, including an approximately 18% drop referenced in one notice and a decline of more than 75% from the class-period high in another. Hagens Berman PROCEPT class-action notice
• Negative Sentiment: The litigation introduces potential legal costs, reputational risk and further scrutiny of PROCEPT’s sales practices, inventory management and underlying procedure demand. The notices do not establish wrongdoing, and no new operational update or company response was provided in the supplied articles. Kahn Swick and Foti PROCEPT securities-fraud notice

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PRCT. Robert W. Baird set a $20.00 price target on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. Piper Sandler decreased their price objective on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. Wall Street Zen raised shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Leerink Partners lowered shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $31.00 to $29.00 in a research report on Thursday, June 11th. Finally, TD Cowen dropped their target price on shares of PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $28.00.

Insiders Place Their Bets

In other PROCEPT BioRobotics news, CEO Larry L. Wood bought 23,900 shares of the business’s stock in a transaction on Friday, August 7th. The stock was purchased at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the transaction, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at $498,315. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 1,000 shares of company stock worth $28,480 in the last three months. 4.00% of the stock is owned by company insiders.

PROCEPT BioRobotics Stock Performance

Shares of PRCT opened at $21.68 on Friday. The firm has a market cap of $1.24 billion, a PE ratio of -11.18 and a beta of 0.89. The stock’s fifty day moving average price is $20.40 and its two-hundred day moving average price is $24.20. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. PROCEPT BioRobotics Corporation has a 1 year low of $16.67 and a 1 year high of $42.43.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The firm had revenue of $94.50 million for the quarter, compared to the consensus estimate of $92.77 million. During the same quarter in the previous year, the company posted ($0.35) EPS. The firm’s revenue was up 19.3% compared to the same quarter last year. On average, equities research analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.